COVID-19 Vaccine Effectiveness Studies against Symptomatic and Severe Outcomes during the Omicron Period in Four Countries in the Eastern Mediterranean Region.

Absolute VE against ICU Admission and/or Death: SARI TND Studies The study-specific VE against ICU admission and/or death in Iran showed a decreasing trend in effect size for the BBIBP-CorV vaccine with an increasing number of doses, although all estimates were non-significant (VE partial 55.5%, 95%CI −7.4% to 81.6%; VE primary 14.1%: 95%CI −48.2% to 50.2%; VE booster 2.7%: 95%CI −74.8% to 45.9%).

also in 47,180 other papers